These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 2557792)

  • 1. Abnormalities of the electron transport chain in idiopathic Parkinson's disease.
    Parker WD; Boyson SJ; Parks JK
    Ann Neurol; 1989 Dec; 26(6):719-23. PubMed ID: 2557792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease.
    Hanagasi HA; Ayribas D; Baysal K; Emre M
    Int J Neurosci; 2005 Apr; 115(4):479-93. PubMed ID: 15809215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic medications inhibit complex I of the electron transport chain.
    Burkhardt C; Kelly JP; Lim YH; Filley CM; Parker WD
    Ann Neurol; 1993 May; 33(5):512-7. PubMed ID: 8098932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron-dependent enzymes in Parkinson's disease.
    Reichmann H; Janetzky B; Riederer P
    J Neural Transm Suppl; 1995; 46():157-64. PubMed ID: 8821051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease.
    Hattori N; Tanaka M; Ozawa T; Mizuno Y
    Ann Neurol; 1991 Oct; 30(4):563-71. PubMed ID: 1665052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of late-onset and slowly progressive mitochondrial myopathy with abnormalities of complexes in electron-transfer system].
    Shibuya S; Wakayama Y; Okayasu H; Tanaka M; Ozawa T
    Rinsho Shinkeigaku; 1988 Oct; 28(10):1147-51. PubMed ID: 2851402
    [No Abstract]   [Full Text] [Related]  

  • 7. Complex I and Parkinson's disease.
    Greenamyre JT; Sherer TB; Betarbet R; Panov AV
    IUBMB Life; 2001; 52(3-5):135-41. PubMed ID: 11798025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Origin and functional consequences of the complex I defect in Parkinson's disease.
    Swerdlow RH; Parks JK; Miller SW; Tuttle JB; Trimmer PA; Sheehan JP; Bennett JP; Davis RE; Parker WD
    Ann Neurol; 1996 Oct; 40(4):663-71. PubMed ID: 8871587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial complex I deficiency in Parkinson's disease.
    Schapira AH; Cooper JM; Dexter D; Clark JB; Jenner P; Marsden CD
    J Neurochem; 1990 Mar; 54(3):823-7. PubMed ID: 2154550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contribution of MPTP to studies on the pathogenesis of Parkinson's disease].
    Mizuno Y
    Rinsho Shinkeigaku; 1989 Dec; 29(12):1494-6. PubMed ID: 2698296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal.
    Schapira AH
    Mov Disord; 1994 Mar; 9(2):125-38. PubMed ID: 8196673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A mitochondrial encephalomyopathy: a case of a defect of complex I in the electron transport chain].
    Shinozawa K; Nishizawa M; Tanaka K; Atsumi T; Ohama E
    Rinsho Shinkeigaku; 1987 Jan; 27(1):41-8. PubMed ID: 3105942
    [No Abstract]   [Full Text] [Related]  

  • 13. Mitochondrial DNA analysis in Parkinson's disease.
    Schapira AH; Holt IJ; Sweeney M; Harding AE; Jenner P; Marsden CD
    Mov Disord; 1990; 5(4):294-7. PubMed ID: 1979656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquinone (coenzyme Q10) and complex I in mitochondrial oxidative disorder of Parkinson's disease.
    Ebadi M; Muralikrishnan D; Pellett LJ; Murphy T; Drees K
    Proc West Pharmacol Soc; 2000; 43():55-63. PubMed ID: 11056957
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease.
    Hattori N; Ikebe S; Tanaka M; Ozawa T; Mizuno Y
    Adv Neurol; 1993; 60():292-6. PubMed ID: 8380521
    [No Abstract]   [Full Text] [Related]  

  • 16. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
    Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
    Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPP(+)-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport.
    Desai VG; Feuers RJ; Hart RW; Ali SF
    Brain Res; 1996 Apr; 715(1-2):1-8. PubMed ID: 8739616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population.
    Varghese M; Pandey M; Samanta A; Gangopadhyay PK; Mohanakumar KP
    J Neurol Sci; 2009 Apr; 279(1-2):39-42. PubMed ID: 19176229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial deficiency of subunits in complex I or IV of patients with mitochondrial myopathies.
    Tanaka M; Nishikimi M; Suzuki H; Ozawa T; Koga Y; Nonaka I
    Biochem Int; 1987 Mar; 14(3):525-30. PubMed ID: 2884999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease.
    Gu M; Cooper JM; Taanman JW; Schapira AH
    Ann Neurol; 1998 Aug; 44(2):177-86. PubMed ID: 9708539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.